Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients

Psychopharmacology

Volumn 220, Issue 3, 2012, Pages 519-528

  Greenbaum, Lior ^a   Smith, Robert C ^b,c   Lorberboym, Mordechai ^d,f   Alkelai, Anna ^a   Zozulinsky, Polina ^a   Lifshytz, Tzuri ^a   Kohn, Yoav ^a   Djaldetti, Ruth ^e,f   Lerer, Bernard ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d WOLFSON MEDICAL CENTER   (Israel)

^e RABIN MEDICAL CENTER   (Israel)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antipsychotic induced parkinsonism; FOG2; Schizophrenia; ZFPM2

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; IODINE 123; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; FEMALE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PARKINSONISM; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VALIDATION PROCESS; ZINC FINGER PROTEIN MULTITYPE 2 GENE;

ADULT; ANTIPSYCHOTIC AGENTS; CORPUS STRIATUM; CROSS-SECTIONAL STUDIES; DNA-BINDING PROTEINS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; ISRAEL; JEWS; LOGISTIC MODELS; MALE; MIDDLE AGED; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSCRIPTION FACTORS; UNITED STATES;

EID: 84858441557     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2499-6     Document Type: Article

References (53)

1. Al Hadithy AF, Wilffert B, Stewart RE, Looman NM, Bruggeman R, Brouwers JR, Matroos GE, van Os J, Hoek HW, van Harten PN (2008) Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors. Am J Med Genet B 147B(6):890-897
2. Al Hadithy AF, Wilffert B, Bruggeman R, Stewart RE, Brouwers JR, Matroos GE, Hoek HW, van Harten PN (2009) Lack of association between antipsychotic-induced parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X. Hum Psychopharmacol 24 (2):123-128
3. Alaerts M, Del-Favero J (2009) Searching genetic risk factors for schizophrenia and bipolar disorder: learn from the past and back to the future. Hum Mutat 30(8):1139-1152
4. Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B (2009) Genome-wide association study of antipsychotic-induced parkin-sonism severity among schizophrenia patients. Psychopharma-cology (Berl) 206(3):491-499
5. Arranz MJ, de Leon J (2007) Pharmacogenetics and pharmacoge-nomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12(8):707-747 (Pubitemid 47172693)
6. Ayd F (1961) A survey of drug-induced extrapyramidal reaction. JAMA 175:1054-1060
7. Basile VS, Masellis M, Potkin SG, Kennedy JL (2002) Pharmacoge-nomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 11(20):2517-2530 (Pubitemid 35174716)
8. Behar DM, Yunusbayev B, Metspalu M, Metspalu E, Rosset S, Parik J, Rootsi S, Chaubey G, Kutuev I, Yudkovsky G, Khusnutdinova EK, Balanovsky O, Semino O, Pereira L, Comas D, Gurwitz D, Bonne-Tamir B, Parfitt T, Hammer MF, Skorecki K, Villems R (2010) The genome-wide structure of the Jewish people. Nature 466(7303):238-242
9. Booij J, Knol RJ (2007) SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. Parkinsonism Relat Disord 13 (Suppl 3):S425-S428 (Pubitemid 351215280)
10. Burn DJ, Brooks DJ (1993) Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study. Neurology 43(3):552-556 (Pubitemid 23088491)
11. Caligiuri MP, Peavy G (2000) An instrumental study of the relationship between extrapyramidal signs and psychosis in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 12 (1):34-39 (Pubitemid 30093686)
12. Cantor AB, Orkin SH (2005) Coregulation of GATA factors by the Friend of GATA (FOG) family of multitype zinc finger proteins. Semin Cell Dev Biol 16(1):117-128 (Pubitemid 40126882)
13. Casey DE (2004) Pathophysiology of antipsychotics drug-induced movement disorders. J Clin Psychiatry 65(supp 9):S25-S28
14. Crowley JJ, Sullivan PF, McLeod HL (2009) Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics 10(2):161-163
15. Ebadi M, Srinivasan SK (1995) Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacol Rev 47(4):575-604 (Pubitemid 26006142)
16. Freyhan FA (1959) Therapeutic implications of differential effects of new phenothiazine compounds. Am J Psychiatry 115(7):577-585
17. Greenbaum L, Strous RD, Kanyas K, Merbl Y, Horowitz A, Karni O, Katz E, Kotler M, Olender T, Deshpande SN, Lancet D, Ben-Asher E, Lerer B (2007) Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet Genomics 17(7):519-528 (Pubitemid 46905218)
18. Greenbaum L, Smith RC, Rigbi A, Strous RD, Teltsh O, Kanyas K, Korner M, Lancet D, Ben-Asher E, Lerer B (2009) Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism the 3′ untranslated region. Pharmacogenomics J 9 (2):103-110
19. Greenbaum L, Alkelai A, Rigbi A, Kohn Y, Lerer B (2010) Evidence for association of the GLI2 gene with tardive dyskinesia in chronic schizophrenia patients. Mov Disord 25(16):2809-2817
20. Gunes A, Dahl ML, Spina E, Scordo MG (2008) Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol 64(5):477-482
21. Haddad PM, Dursun SM (2008) Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 23(Suppl 1):S15-S26
22. Hansen TE, Casey DE, Hoffman WF (1997) Neuroleptic intolerance. Schizophr Bull 23(4):567-582 (Pubitemid 27485968)
23. Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, Martin T, Litvinjuk Y, Giladi N (2001) Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm 108 (11):1299-1308 (Pubitemid 33141304)
24. Higa M, Ohnuma T, Maeshima H, Hatano T, Hanzawa R, Shibata N, Sakai Y, Suzuki T, Arai H (2010) Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: results from the Juntendo University Schizophrenia Projects (JUSP). Neurosci Lett 469(1):55-59
25. Hirose G (2006) Drug induced parkinsonism: a review. J Neurol 253 (Suppl 3):iii22-iii24
26. Hoene V, Fischer M, Ivanova A, Wallach T, Berthold F, Dame C (2009) GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes. Br J Cancer 101 (8):1481-1489
27. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181-184
28. Janno S, Holi MM, Tuisku K, Wahlbeck K (2005) Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurol 5(1):5
29. Kasten M, Brüggemann N, König IR, Doerry K, Steinlechner S, Wenzel L, Lohmann K, Klein C, Lencer R (2011) Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility. Psychopharmacology (Berl) 214(3):729-736
30. Lerner V, Libov I, Kapstan A, Miodownik C, Dwolatzky T, Levine J (2007) The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffec-tive patients residing in the southern region of Israel. Isr J Psychiatry Relat Sci 44(1):20-28
31. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209-1223
32. LorberboymM, Treves TA, Melamed E,LamplY, HellmannM,Djaldetti R (2006) [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 21 (4):510-514
33. Lu JR, McKinsey TA, Xu H, Wang DZ, Richardson JA, Olson EN (1999) FOG-2, a heart- and brain-enriched cofactor for GATA transcription factors. Mol Cell Biol 19(6):4495-4502 (Pubitemid 29242022)
34. Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, Oakes D, Seibyl J (2001) [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57 (11):2089-2094 (Pubitemid 33126879)
35. Medinar C, Kramer MD, Kurland AA (1962) Biperiden in the treatment of phenothiazine-induced extrapyramidal reactions. JAMA 182:1127-1128
36. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10(1):79-104 (Pubitemid 40139590)
37. Mozley PD, Schneider JS, Acton PD, Plössl K, Stern MB, Siderowf A, Leopold NA, Li PY, Alavi A, Kung HF (2000) Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 41 (4):584-589 (Pubitemid 30207731)
38. Owen MJ, Craddock N, O'Donovan MC (2010) Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia. Arch Gen Psychiatry 67(7):667-673
39. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81 (3):559-575 (Pubitemid 47330214)
40. Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, Normand SL, Mamdani M, Lee PE, Li P, Bronskill SE, Marras C, Gurwitz JH (2005) Atypical antipsychotics and parkinsonism. Arch Intern Med 165(16):1882-1888 (Pubitemid 41352083)
41. Simpson G, Angus MP (1970) Scale for assessment extrapyramidal side effects. Acta Psychiatr Scand 212:11-19
42. Smith R, Lindenmayer J-P, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A (2005) Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol 8(2):183-194
43. Stephen PJ, Williamson J (1984) Drug-induced parkinsonism in the elderly. Lancet 2(8411):1082-1083 (Pubitemid 15211533)
44. Sullivan PF (2007) Spurious genetic associations. Biol Psychiatry 61 (10):1121-1126 (Pubitemid 46669468)
45. Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, Liu W, Downing AM, Lieberman J, Close SL (2008) Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 13(6):570-584 (Pubitemid 351704941)
46. Svensson EC, Tufts RL, Polk CE, Leiden JM (1999) Molecular cloning of FOG-2: a modulator of transcription factor GATA-4 in cardiomyocytes. Proc Natl Acad Sci U S A 96(3):956-961 (Pubitemid 29072165)
47. Tenback DE, van Harten PN, Slooff CJ, van Os J (2006) Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 163(8):1438-1440 (Pubitemid 44464418)
48. Tevosian SG, Albrecht KH, Crispino JD, Fujiwara Y, Eicher EM, Orkin SH (2002) Gonadal differentiation, sex determination and normal Sry expression in mice require direct interaction between transcription partners GATA4 and FOG2. Development 129 (19):4627-4634 (Pubitemid 35203743)
49. Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steinmayr M, Vampini C, Pilleri M, Moretto G, Fiaschi A, Smania N, Giorgetti P, Antonini A (2008) [123I]FP-CIT SPET imaging in drug-induced Parkinsonism. Mov Disord 23(13):1825-1829
50. Tinazzi M, Antonini A, Bovi T, Pasquin I, Steinmayr M, Moretto G, Fiaschi A, Ottaviani S (2009) Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol 256(6):910-915
51. van den Oord EJ, Kuo PH, Hartmann AM, Webb BT, Möller HJ, Hettema JM, Giegling I, Bukszár J, Rujescu D (2008) Genome-wide association analysis followed by a replication study implicates a novel candidate gene for neuroticism. Arch Gen Psychiatry 65(9):1062-1071
52. Varrone A, Halldin C (2010) Molecular imaging of the dopamine transporter. J Nucl Med 51(9):1331-1334
53. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC (2003) [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry 74(3):294-298 (Pubitemid 36259350)